The Monoclonal Antibody Cocktail in SARS-CoV 2: A Bonanza for Patients With Chronic Lymphocytic Leukemia?

Authors

  • Brunda M S Aster CMI hospital, 43/2, New Airport Road, NH.7, Sahakara Nagar, Bengaluru, Karnataka 560092.
  • Arushi Mohan Aster CMI hospital, 43/2, New Airport Road, NH.7, Sahakara Nagar, Bengaluru, Karnataka 560092.
  • Anant Patil Padmashree Dr. D.Y. Patil University Sector 15, Plot no 50, CBD Belapur Navi Mumbai (District Mumbai) Maharashtra, India - 400614
  • Hashif P Aster CMI hospital, 43/2, New Airport Road, NH.7, Sahakara Nagar, Bengaluru, Karnataka 560092.
  • Prakash Doraiswamy Aster CMI hospital, 43/2, New Airport Road, NH.7, Sahakara Nagar, Bengaluru, Karnataka 560092.
  • Samriddha Thapa Patan Academy of health sciences, Lagankhel, Lalitpur,Nepal.

Keywords:

medicine, pulmonology

Abstract

Monoclonal antibody cocktail is currently one of the most promising approaches being studied in the management of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). We present a case of an elderly patient with coronavirus disease (COVID-19) and Chronic lymphocytic leukaemia (CLL) who had recurrent episodes of desaturation and admission in intensive care unit (ICU) despite receiving the treatment for moderate to severe COVID-19. After careful selection, weighing the benefits and risks, the patient was started on the combination of the two monoclonal antibodies, casirivimab and imdevimab. The results suggest that this could be a game changer in COVID-19 with a focused approach of management of COVID-19 positive patients especially in the vulnerable population.

References

. Coronavirus.Who.int.(2021).Internet.https://www.who.int/health-topics/coronavirus#tab=tab_1. Accessed: 19 October, 2021.

. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA. “Case fatality rate of cancer patients with COVID-19 in a New York hospital system”. Cancer discovery. 2020 Jul 1;10(7):935-41

. “FDA: fact sheet for health care providers emergency use authorization (eua) of regen-cov (casirivimab and imdevimab)”. [Internet]. https://www.fda.gov/media/145611/download Accessed :16 October, 2021.

. Science Brief: “COVID-19 Vaccines and Vaccination”.Internet. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html updated on September 15, 2021 Accessed: October 19,2021.

. Mukkamalla SKR, Taneja A, Malipeddi D, et al. In: StatPearls .Internet. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/ .[Updated 2021 Oct 1].. Treasure Island (FL): StatPearls Publishing; 2021 Jan.

. Giannakoulis VG, Papoutsi E, Siempos II. “Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data”. JCO global oncology. 2020 Jun;6:799-808.

. “Therapeutic management of hospitalized adults with covid-19”.Internet. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/. Revised :25 August, 2021.Accessed: 19 October,2021.

. Horby PW, Pessoa-Amorim G, Peto L. for “the RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial”. medRxiv. 2021:12-24.

. Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, Spata E, Staplin N, Emberson JR, Prudon B, Hine P, Brown T. “Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”. medRxiv. 2021 Jan 1.

. O’Brien, M. P., Al., E. the Covid-19 Phase 3 Prevention Trial Team*, Pharmaceuticals, A. A. F. R., Others, W. Z. and, Others, G. L. and, Others, G. C. and, D. M. Weinreich and Others, A. R. Falsey and Others, & T. T. Shimabukuro and Others “Subcutaneous regen-COV antibody combination to prevent covid-19”: Nejm. New England Journal of Medicine. Retrieved October 7, 2021

. Forconi F, Moss P. “Perturbation of the normal immune system in patients with CLL”. Blood, The Journal of the American Society of Hematology. 2015 Jul 30;126(5):573-81.

. Hardeman, P. et al., 1970. “Does rituximab cause depletion of T-cells in multiple sclerosis and Neuromyelitis Optica? (P2.158)”: Semantic scholar. undefined. [Online]Available at: https://www.semanticscholar.org/paper/Does-Rituximab-Cause-Depletion-of-T-Cells-in-and-Hardeman-Mann/48f22881adfeaccb5a0d1ab8aa94055be5bce78a [Accessed March 31, 2022].

. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X. “Human neutralizing antibodies elicited by SARS-CoV-2 infection”. Nature. 2020 Aug;584(7819):115-9.

. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM. “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail”. Science. 2020 Aug 21;369(6506):1010-4.

. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM. “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail”. Science. 2020 Aug 21;369(6506):1010-4.

. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfo L, Joffe E. “Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood”. The Journal of the American Society of Hematology. 2021 Jun 10;137(23):3165-73.

Downloads

Published

2022-04-09

How to Cite

M S , B. ., Mohan, A., Anant Patil, P, H., Doraiswamy , P. ., & Thapa, S. (2022). The Monoclonal Antibody Cocktail in SARS-CoV 2: A Bonanza for Patients With Chronic Lymphocytic Leukemia?. International Journal of Sciences: Basic and Applied Research (IJSBAR), 62(1), 198–204. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/13924

Issue

Vol. 62 No. 1 (2022)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.